Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients : hurdles and perspectives for clinical implementation
Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to address emerging questions to facilitate implementation in clinics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 18 vom: 01. Dez., Seite 895-900 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gagno, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8A1O1M485B |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0198 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364467215 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364467215 | ||
| 003 | DE-627 | ||
| 005 | 20231227135935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0198 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM364467215 | ||
| 035 | |a (NLM)37955064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gagno, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients |b hurdles and perspectives for clinical implementation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to address emerging questions to facilitate implementation in clinics | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Ctrough | |
| 650 | 4 | |a gastrointestinal stromal tumor | |
| 650 | 4 | |a imatinib | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a precision dosing | |
| 650 | 4 | |a therapeutic drug monitoring | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Fratte, Chiara Dalle |e verfasserin |4 aut | |
| 700 | 1 | |a Posocco, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Buonadonna, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Fumagalli, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Guardascione, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Toffoli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchin, Erika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 18 vom: 01. Dez., Seite 895-900 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:18 |g day:01 |g month:12 |g pages:895-900 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0198 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 18 |b 01 |c 12 |h 895-900 | ||